Spots Global Cancer Trial Database for akt inhibitor
Every month we try and update this database with for akt inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer | NCT01266954 | Solid Tumours | GSK2141795 | 18 Years - 85 Years | GlaxoSmithKline | |
| Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma | NCT01428492 | Multiple Myelom... | GSK2110183 Bortezomib Dexamethasone | 18 Years - | Novartis | |
| A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795 | NCT00920257 | Cancer | GSK2141795 | 18 Years - | GlaxoSmithKline | |
| Continuation Study of the Oral AKT Inhibitor GSK2110183 | NCT01531894 | Cancer | GSK2110183 (afu... | 18 Years - 80 Years | Novartis | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma | NCT01445587 | Cancer | Part 1; Cohort ... Part 1; Cohort ... Part 2; Stage 1 Part 2, Stage 2 | 18 Years - | GlaxoSmithKline | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients | NCT02177682 | Neoplasms, Haem... | Afuresertib | 20 Years - | Novartis | |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | NCT02240212 | Cancer | Afuresertib Paclitaxel | 18 Years - | Novartis | |
| A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma | NCT01445587 | Cancer | Part 1; Cohort ... Part 1; Cohort ... Part 2; Stage 1 Part 2, Stage 2 | 18 Years - | GlaxoSmithKline | |
| Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | NCT01827644 | Cancer | Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... | 18 Years - 40 Years | GlaxoSmithKline | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | NCT04586270 | Advanced or Met... | TAS0612 | 18 Years - | Taiho Oncology, Inc. | |
| K-BASKET, TAS-117, PI3K/AKT Gene Aberration | NCT03017521 | Solid Tumor, Ad... | TAS-117 | 19 Years - | Yonsei University | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline | |
| Safety, Pharmacokinetics (PK) of AKT and MEK Combination | NCT01138085 | Cancer | GSK1120212 GSK2141795 | 18 Years - | GlaxoSmithKline | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations | NCT04770246 | Advanced or Met... Advanced or Met... | TAS-117 TAS-117 TAS-117 TAS-117 | 12 Years - | Taiho Oncology, Inc. | |
| Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers | NCT01827644 | Cancer | Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... Afuresertib GC ... Afuresertib HPM... Afuresertib ECT... | 18 Years - 40 Years | GlaxoSmithKline | |
| PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer | NCT02423603 | Metastatic Brea... | Paclitaxel AZD5363 Placebo | 18 Years - | Queen Mary University of London | |
| A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers | NCT01476137 | Cancer | GSK1120212 GSK2110183 | 18 Years - | GlaxoSmithKline | |
| Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib | NCT02040480 | Cancer | GSK2110183 Gela... GSK2110183 IR T... | 18 Years - 40 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
